TherapeuticsMD, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue, net: | ||
| License revenue | $724 | $393 |
| Operating expenses: | ||
| General and administrative | 1,353 | 1,491 |
| Write-off of patents | — | 88 |
| Depreciation & amortization | 94 | 95 |
| Total operating expenses | 1,447 | 1,674 |
| Loss from operations | (723) | (1,281) |
| Other income: | ||
| Interest income, net | 41 | 29 |
| Sublease income | 517 | 410 |
| Miscellaneous income | 268 | 174 |
| Total other income, net | 826 | 613 |
| Income (loss) from continuing operations before income taxes | 103 | (668) |
| Income tax benefit | — | 32 |
| Income (loss) from continuing operations, net of income taxes | 103 | (636) |
| Loss from discontinued operations, net of income taxes | (8) | (17) |
| Net income (loss) | $95 | $(653) |
| Income (loss) per common share, basic and diluted: | ||
| Continuing operations | $0.01 | $(0.06) |
| Discontinued operations, net | 0.00 | 0.00 |
| Net income (loss) per common share, basic and diluted | $0.01 | $(0.06) |
| Weighted average common shares, basic | 11,574 | 11,552 |
| Weighted average common shares, diluted | 11,640 | 11,552 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.